MedTrace Logo

INNO-105 in Patients With Solid Tumors

NCT00255333 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2007-05-14

No results posted yet for this study

Summary

The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer drug, are being studied in patients with solid tumors.

Conditions

Interventions

DRUG

INNO-105

Sponsors & Collaborators

  • Innovive Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Casey Cunningham, MD · Mary Crowley Medical Research Center

  • Edward Sausville, M.D., Ph.D. · University of Maryland Greenebaum Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255333 on ClinicalTrials.gov